ArticleJournal of virology2018
Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 46 citations in OpenAlex.
- Therapeutic advances in Marburg virus disease: from experimental treatments to vaccine development.Annals of medicine and surgery (2012) · 2025Review
- Marburg Virus Medical Countermeasures.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Current perspectives on vaccines and therapeutics for Lassa Fever.Virology journal · 2024Review
- Filovirus vaccines as a response paradigm for emerging infectious diseases.NPJ vaccines · 2024Review
- An update on nonhuman primate usage for drug and vaccine evaluation against filoviruses.Expert opinion on drug discovery · 2024Review
- Efficacy and Immunogenicity of a Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine in Cynomolgus Macaques.Viruses · 2024Article
- Design of universal Ebola virus vaccine candidates via immunofocusing.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Article
- A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus.The Journal of infectious diseases · 2023Article
- Design of universal Ebola virus vaccine candidatesbioRxiv : the preprint server for biology · 2023Article
- Emergence of Marburg virus: a global perspective on fatal outbreaks and clinical challenges.Frontiers in microbiology · 2023Review
- Natural history ofEmerging microbes & infections · 2022Article
- Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs.Vaccines · 2022Article
- An introduction to the Marburg virus vaccine consortium, MARVAC.PLoS pathogens · 2022Article
- Article
- Review
- A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge.PLoS neglected tropical diseases · 2022Article
- Current state of Ebola virus vaccines: A snapshot.PLoS pathogens · 2021Article
- Vesicular Stomatitis Virus: From Agricultural Pathogen to Vaccine Vector.Pathogens (Basel, Switzerland) · 2021Review
- A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector.Vaccines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
Abstract
Previous studies demonstrated that a single intramuscular (i.m.) dose of an attenuated recombinant vesicular stomatitis virus (rVSV) vector (VesiculoVax vector platform; rVSV-N4CT1) expressing the glycoprotein (GP) from the Mayinga strain of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.